MFS
OVID icon

Mirabella Financial Services’s Ovid Therapeutics OVID Stock Holding History

Mirabella Financial Services’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,500
Closed -$61K – 647
2022
Q1 		$61K Buy
+19,500
New +$61.3K 0.01% 469

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Mirabella Financial Services's OVID Position: Q2 2022 in Review

Mirabella Financial Services sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 19,500 shares — an estimated $61K sold.

Mirabella Financial Services first reported a position in OVID in Q1 2022 and held it in 1 quarter. The position peaked at $61K in Q1 2022. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Mirabella Financial Services reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mirabella Financial Services sold 19,500 Ovid Therapeutics shares in Q2 2022, an estimated $61K.
  • Mirabella Financial Services first reported a position in Ovid Therapeutics in Q1 2022 and held it in 1 quarter.
  • Mirabella Financial Services's Ovid Therapeutics position peaked at $61K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Mirabella Financial Services's 13F filing for Q2 2022, filed 12 Aug 2022.